论文部分内容阅读
目的探讨阿托伐他汀对口服降压药后血压控制为轻度高血压患者的影响。方法选取2014年1月~2014年12月间在本院就诊的经药物治疗后血压控制为轻度高血压的患者776例,随机分为研究组和对照组,每组388例。两组均常规给予口服降压药治疗,研究组加服阿托伐他汀20mg/d,进行两年的随访,记录血压水平和治疗相关不良反应发生情况。结果两年后,研究组患者治疗总有效率高于对照组,差异有统计学意义(P<0.05)。随访过程中研究组加服降压药的患者比例低于对照组,差异有统计学意义(P<0.05);研究组与对照组不良反应发生率之间无统计学差异(P>0.05);两组均无血压急剧升高、肝肾功能损伤等严重不良反应。两组患者治疗前血压水平之间差异无统计学意义(P>0.05);治疗后研究组和对照组患者收缩压和舒张压均低于治疗前,研究组患者降压下降幅度大于对照组,差异均有统计学意义(P<0.01)。结论阿托伐他汀可有效降低血压控制为轻度高血压患者的血压水平和稳定性,且安全性较佳,值得推广应用。
Objective To investigate the effect of atorvastatin on blood pressure control in patients with mild hypertension after oral antihypertensive drugs. Methods A total of 776 patients with mild hypertension controlled by medical treatment in our hospital from January 2014 to December 2014 were randomly divided into study group and control group with 388 cases in each group. The two groups were given routine oral antihypertensive drugs, the study group plus atorvastatin 20mg / d, for two years follow-up, recording blood pressure levels and treatment-related adverse reactions. Results Two years later, the total effective rate of treatment in study group was higher than that in control group, with significant difference (P <0.05). The proportion of patients receiving antihypertensive drugs during the follow-up period was lower than that of the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the study group and the control group (P> 0.05). No sharp increase in blood pressure, liver and kidney dysfunction and other serious adverse reactions. There was no significant difference between the two groups in the blood pressure before treatment (P> 0.05). After treatment, the systolic and diastolic blood pressure of study group and control group were lower than that before treatment, and the decrease of blood pressure in study group was larger than that of control group The differences were statistically significant (P <0.01). Conclusions Atorvastatin can effectively decrease the blood pressure and the stability of blood pressure control in patients with mild hypertension, and it is safe and worthy of promotion.